Try our beta test site

An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: November 15, 2012
Last updated: April 2, 2016
Last verified: April 2016
This multicenter, prospective, observational study will evaluate the use in clinical practice and the efficacy and safety of Pegasys (peginterferon alfa-2a) in Chinese patients with HBeAg negative chronic hepatitis B. Patients receiving Pegasys according to the local label will be followed for the duration of their treatment and for one year after cessation of treatment.

Hepatitis B, Chronic

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Incidence of sustained suppression of HBV DNA <2000 IU/mL one year after treatment cessation [ Time Frame: approximately 4 years ]

Secondary Outcome Measures:
  • Incidence of suppression of HBV DNA <2000 IU/mL at the end of treatment and 6 months post-treatment [ Time Frame: approximately 4 years ]
  • Incidence of HBV DNA undetectable (<400 IU/mL) at the end of treatment and 1 year post-treatment [ Time Frame: approximately 4 years ]
  • Incidence of HBsAg loss/seroconversion [ Time Frame: approximately 4 years ]
  • Incidence of normalization of serum ALT levels [ Time Frame: approximately 4 years ]
  • Dosage/schedule of Pegasys treatment in real-life clinical setting [ Time Frame: approximately 4 years ]
  • Clinical/demographic patient characteristics at initiation of treatment [ Time Frame: approximately 4 years ]
  • Safety: Incidence of adverse events [ Time Frame: approximately 4 years ]

Enrollment: 978
Study Start Date: November 2012
Estimated Study Completion Date: April 2017
Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Chinese patients with HBeAg negative chronic hepatitis B receiving treatment with Pegasys

Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Treatment with Pegasys according to label and standard clinical practice
  • HBeAg negative serologically proven chronic hepatitis B with or without cirrhosis
  • Serum ALT > ULN (upper limit of normal) but </= 10 x ULN
  • HBV DNA >/= 2000 IU/mL

Exclusion Criteria:

  • Contraindications to Pegasys as detailed in the label
  • Co-infection with hepatitis A, hepatitis C or HIV
  • Pregnant or lactating women
  • Patients should not receive concomitant therapy with telbivudine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01730508

  Hide Study Locations
Baoding, China
Beijing, China, 100011
Beijing, China, 100039
Beijing, China, 100050
Beijing, China, 100069
Beijing, China, 100083
Beijing, China, 100730
Changchun, China, 130021
Changchun, China
Changsha, China, 410007
Changsha, China, 410013
Changzhou, China, 213001
Chengdu, China, 610041
Chongqing, China, 400010
Chongqing, China, 400016
Chongqing, China, 400038
Dalian, China, 116031
Foshan, China
Foushan, China
Fuzhou, China, 350025
Guangzhou, China, 510060
Guangzhou, China, 510080
Guangzhou, China, 510180
Guangzhou, China, 510405
Guangzhou, China, 510515
Guangzhou, China, 510630
Guangzhou, China
Haikou, China, 570311
Hangzhou, China, 310003
Hangzhou, China
Harbin, China
Hefei, China, 230022
Huai'an, China, 223001
Jiangmen, China, 529000
Jiangyin, China
Jinan, China, 250021
Kunming, China, 650041
Lanzhou, China
Lianyungang, China, 222002
Liuzhou, China
LuZhou, China, 646000
Nanchang, China, 330002
Nanjing, China, 210003
Nanjing, China, 210036
Nanjing, China
Nanning, China, 530011
Nanning, China, 530021
Ningbo, China
Ordos, China
Qingdao, China, 266033
Shanghai, China, 200025
Shanghai, China, 201508
Shanghai, China, 201999
Shanghai, China
Shantou, China, 515041
Shen Zhen, China, 518020
ShenYang, China, 110004
Shenyang, China
Shijiazhuang, China, 050031
Shijiazhuang, China, 050082
Suining, China, 629000
Suzhou, China
Taiyuan, China
Taizhou, China, 225300
Tianjin, China, 300192
Tianjin, China
Urumqi, China, 830001
Urumqi, China, 830054
Wenzhou, China, 325000
Wenzhou, China, 325200
Wuhan, China, 430030
Wuxi, China, 214005
Xi'an, China, 710038
Xiamen, China
Xingtai, China
Xuzhou, China, 221004
Yancheng, China, 224005
Yangzhou, China, 225009
Yichang, China
Zhaoqing, China, 526020
Zhengzhou, China, 450003
Zhenjiang, China, 212005
Zhoushan, China, 316000
Zhuhai, China, 519099
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT01730508     History of Changes
Other Study ID Numbers: ML28516 
Study First Received: November 15, 2012
Last Updated: April 2, 2016

Additional relevant MeSH terms:
Hepatitis A
Hepatitis, Chronic
Hepatitis B
Hepatitis B, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Peginterferon alfa-2a
Antiviral Agents
Anti-Infective Agents processed this record on February 23, 2017